Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9970686 | 0.88 | GAA (0.61) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL20117984 | 0.88 | GAA (0.61) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL29368367 | 0.88 | GAA (0.61) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL2488992 | 0.86 | GAA (0.58) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL8059674 | 0.86 | GAA (0.58) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL22753513 | 0.86 | GAA (0.58) | GAATDP1HTTMAPK1LMNA | |
| Propazine SCHEMBL67521 | 0.86 | GAA (1.00) | GAATDP1HTTMAPK1LMNA | |
| Propazine SCHEMBL8539531 | 0.86 | GAA (1.00) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL9970677 | 0.84 | GAA (0.56) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL11689362 | 0.84 | GAA (0.56) | GAATDP1HTTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-20210046145-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| US-10011628-B2 | Multivalent sialic acid derivatives | ADENOVIR PHARMA AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-10011628-B2 | Multivalent sialic acid derivatives | ADENOVIR PHARMA AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-20180120694-A1 | HOLOGRAM RECORDING COMPOSITION, HOLOGRAM RECORDING MEDIUM, AND METHOD OF PRODUCING HOLOGRAM RECORDING MEDIUM | SONY CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20160207955-A1 | MULTIVALENT SIALIC ACID DERIVATIVES | ADENOVIR PHARMA AB (SE) | 2016-07-21 | — | — | US | disclosed |
| US-6130332-A | USING A GROUP 8 METAL CATALYST AND ALDEHYDES OR KETONE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-10 | — | — | US | disclosed |
| US-6124381-A | CURING ACCELERATOR IS A 2-((MONO- OR DI-ALKYL)AMINO, MORPHOLINO, PIPERIDINO, METHYL OR PHENYL)-4,6-SUBSTITUTED DIAMINO-1,3,5-TRIAZINE OF GIVEN FORMULA; POT LIFE, STORAGE STABILITY, AND WORKABILITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
| EP-0834523-A1 | EPOXY/ACID ANHYDRIDE COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-04-08 | — | — | EP | disclosed |
| EP-0760369-A1 | PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-05 | — | — | EP | disclosed |
| US-5534573-A | FLAME RETARDANTS | COURTAULDS PLC (GB) | 1996-07-09 | — | — | US | disclosed |
| US-4186265-A | BY EXTRACTION WITH AQUEOUS ACID OR BY ACIDIFICATION OF ALKALINE FILTRATE FOLLOWED BY EXTRACTION WITH WATER-IMMISCIBLE SOLVENT | CIBA-GEIGY CORPORATION (US) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | GAA 3737/4885TDP1 4564/4885HTT 1692/4885 |
| US-20210046145-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | GAA 3737/4885TDP1 4564/4885HTT 1692/4885 |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | VIP, NGLY1, GRPR | GAA 3314/4885TDP1 4302/4885HTT 2023/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | GAA 3737/4885TDP1 4564/4885HTT 1692/4885 |
| US-20160207955-A1 | MULTIVALENT SIALIC ACID DERIVATIVES | SIGLEC9, NEU3, NEU1 | GAA 454/4885TDP1 4206/4885HTT 3968/4885 |
| US-10011628-B2 | Multivalent sialic acid derivatives | SIGLEC9, NEU3, NEU1 | GAA 454/4885TDP1 4206/4885HTT 3968/4885 |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | GAA 3737/4885TDP1 4564/4885HTT 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.